Furthermore, an antibody drug conjugates (ADC), fam-trastuzumab deruxtecan (T-DXd) has good effects in HER2 low patients with advanced breast cancer according to phase III Destiny-Breast04 Trial [43,49,50]. The gene discussed is ERBB2; the disease is breast carcinoma.